

Special Issue

Chromatin-Remodeling Factors in Cancer Cells

Message from the Guest Editor

Chromatin-remodeling and transcription factors are key regulators of the gene expression programs that govern cancer initiation, progression, and response to therapy. Their dysregulation alters chromatin architecture, reprograms cellular states, and creates vulnerabilities that can be therapeutically exploited. As our tools for interrogating the cancer epigenome evolve, new opportunities are emerging for targeting these pathways with precision. This Special Issue invites original research and reviews exploring the roles of chromatin remodelers and transcription factors in cancer biology and treatment. We welcome studies employing advanced methodologies such as CRISPR-based functional screens, single-cell epigenomics, chromatin conformation capture (e.g., Hi-C), ATAC-seq, and integrative multiomics. Submissions highlighting therapeutic strategies, ranging from small molecule inhibitors and PROTACs to epigenetic drugs and combination therapies, are strongly encouraged. Through this Special Issue, we will showcase cutting-edge research that advances our understanding of epigenetic and transcriptional control in cancer, aiming to inform next-generation therapeutic strategies.

Guest Editor

Dr. Sudhakar Jha

Department of Physiological Sciences, College of Veterinary Medicine,
Oklahoma State University, Stillwater, OK 74078, USA

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/239168

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)